IV Tulisokibart

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Crohn's DiseaseUlcerative Colitis

Phase 3

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

Active, not recruitingNCT06052059

Merck Sharp & Dohme LLCUlcerative Colitis

Start: 2023-10-25End: 2029-08-01Target: 1020Updated: 2026-03-13

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

RecruitingNCT06430801

Merck Sharp & Dohme LLCCrohn's Disease

Start: 2024-06-05End: 2029-11-12Target: 1200Updated: 2026-09-17